Vicente Villanueva

Vicente Villanueva

Auto-generated profile, based on publicly available information

Vicente Villanueva

Hospital Universitario y Politécnico La Fe

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
ODOrrin Devinsky
Orrin Devinsky
APAnup D. Patel
Anup D. Patel
JCJ. Helen Cross
J. Helen Cross
VVVicente Villanueva
Vicente Villanueva
EWElaine C. Wirrell
Elaine C. Wirrell
SZSameer M. Zuberi
Sameer M. Zuberi
Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox–Gastaut syndrome, a severe developmental epileptic encephalopathy.

13 November 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
LKLinda Kalilani
Linda Kalilani
XSXuezheng Sun
Xuezheng Sun
BPBarbara Pelgrims
Barbara Pelgrims
MNMatthias Noack‐Rink
Matthias Noack‐Rink
VVVicente Villanueva
Vicente Villanueva

1 May 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
GKG.L. Krauss
G.L. Krauss
JSJ.M. Serratosa
J.M. Serratosa
VVV. Villanueva
V. Villanueva
MEM. Endziniene
M. Endziniene
ZHZ. Hong
Z. Hong
ALA. Laurenza
A. Laurenza
Objective: To evaluate the efficacy and safety of perampanel 2, 4, and 8 mg/day added to 1–3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures. Methods: During this double-blind, placebo-controlled trial, patients with persisting seizures on 1–3 AEDs were randomized to perampanel 2, 4, and 8 mg/day or placebo following a 6-week baseline phase. Perampanel was titrated weekly by 2 mg/day and maintained at the dose achieved for 13 weeks. Primary endpoints were median percent change in seizure frequency and 50% responder rate. Analysis of covariance was performed on all treated patients with any seizure data (recorded in daily diaries) in the double-blind phase. Results: A total of 706 patients were randomized and received trial medication; 623 completed the trial. Median percent change in seizure frequency—the primary efficacy endpoint—was −10.7%, −13.6%, −23.3%, and −30.8% for placebo, perampanel 2, 4, and 8 mg/day, respectively. The difference from placebo was statistically significant for perampanel 4 mg/day (p = 0.0026) and 8 mg/day (p < 0.0001). The corresponding 50% responder rates were 17.9%, 20.6%, 28.5%, and 34.9%. The difference from placebo was statistically significant for perampanel 4 mg/day (p = 0.0132) and 8 mg/day (p = 0.0003). An apparent dose response was suggested for dizziness, which was the most frequent treatment-emergent adverse event. Conclusions: This trial demonstrated that adjunctive perampanel effectively reduced seizure frequency and possessed a favorable tolerability profile in patients ≥12 years with partial-onset seizures (with or without secondary generalization), with a minimum effective dose of 4 mg/day. Classification of Evidence: This study provides Class I evidence that 4 and 8 mg/day doses of adjunctive perampanel are effective and tolerated in reducing partial-onset seizures.

1 October 2016 in Epilepsy Research
Verified
Journal Article
Closed access
VVV. Villanueva
V. Villanueva
MGM. Garcés
M. Garcés
FLF.J. López-González
F.J. López-González
XRX. Rodriguez-Osorio
X. Rodriguez-Osorio
MTM. Toledo
M. Toledo
JBJ.J. Baiges
J.J. Baiges

31 July 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
VVVicente Villanueva
Vicente Villanueva
JMJavier Montoya
Javier Montoya
ACAscension Castillo
Ascension Castillo
JMJosé Á. Mauri‐Llerda
José Á. Mauri‐Llerda
PGPau Giner
Pau Giner
JSJavier Salas‐Puig
Javier Salas‐Puig

9 December 2021 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
ECElena Cardenal‐Muñoz
Elena Cardenal‐Muñoz
SAStéphane Auvin
Stéphane Auvin
VVVicente Villanueva
Vicente Villanueva
JCJ. Helen Cross
J. Helen Cross
SZSameer M. Zuberi
Sameer M. Zuberi
JMJosé Ángel Aibar Moreno
José Ángel Aibar Moreno
Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic encephalopathy affecting 1 in 16 000 live births and characterized by a drug‐resistant epilepsy, cognitive, psychomotor, and language impairment, and behavioral disorders. Evidence suggests that optimal treatment of seizures in DS may improve outcomes, even though neurodevelopmental impairments are the likely result of both the underlying genetic variant and the epilepsy. We present an updated guideline for DS diagnosis and treatment, taking into consideration care of the adult patient and nonpharmaceutical therapeutic options for this disease. This up‐to‐date guideline, which is based on an extensive review of the literature and culminates with a new treatment algorithm for DS, is a European consensus developed through a survey involving 29 European clinical experts in DS. This guideline will serve professionals in their clinical practice and, as a consequence, will benefit DS patients and their families.